Comparative Study of Two Tetanus Toxoid Vaccination Strategies: Cold Chain Versus Controlled Temperature Chain

Not Applicable

Completed

• Conditions: Tetanus; Tetanus Vaccine
• Interventions: Biological: Tetanus toxoid vaccine

• Registration Number: NCT01559597
• Lead Sponsor: Epicentre

Brief Summary

The purpose of this study is to determine the effectiveness, safety and feasibility of a tetanus toxoid (TT) vaccination strategy relying on the maintenance of vaccines in a controlled temperature chain (CTC). The CTC is defined as the storage and transport of vaccines within a temperature range appropriate to the heat stability profile of TT vaccine. In this study vaccines are transported and stored in the cold chain up to district level. From district to beneficiary level vaccines are exposed to ambient temperatures during a limited period of time.

In an initial phase, the stability of 3 lots of TT vaccine kept in CTC is determined. For this, the potency, safety, pH and adsorption of vaccines maintained in CTC will be tested in the laboratory and compared to vaccines that have been maintained in cold chain. If all parameters (i.e. potency, safety, pH and adsorption) are above WHO specifications the strategy in CTC will be used.

Only if the laboratory results are adequate, villages will be assigned to one of the vaccination strategies. All women between 14 to 49 years of age in the selected villages who fulfill the inclusion criteria will be invited to participate.

In order to determine the baseline anti-tetanus protection, TT vaccination history will be collected from all participants using a standardized questionnaire. Women who have already received at least 2 doses of TT vaccine will be excluded from the study. Moreover, blood will be collected from all participants to later verify in laboratory the baseline protection.

A first dose of TT vaccine will be given according to the assigned strategy (CTC or cold chain). Four weeks after the 1st vaccination, a second TT vaccine will be given using the same strategy employed for the first dose. Finally, four weeks after the second dose, a blood sample will be collected from all participants who received two doses of vaccine. The serological responses will be compared in the group that received two doses of TT vaccine maintained in cold chain ant the group that received two doses of vaccine maintained in CTC.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-03-19
• Study First Submitted QC: 2012-03-19
• Study First Posted: 2012-03-21
• Study Start: 2012-11
• Status Verified: 2013-02
• Primary Completion: 2013-03
• Study Completion: 2013-03
• Last Update Submitted: 2013-05-01
• Last Update Posted: 2013-05-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 2129

Inclusion Criteria

• Women aged between 14 to 49 years of age
• Living in the district of Moïssala, Chad
• Have no proof of previous vaccination or previous vaccination is not greater than 1 dose of vaccine
• Previous dose received more than 1 month before
• Consented to be included in the study

Read More

Exclusion Criteria

• Allergic reaction to previous tetanus vaccination
• Severe febrile illness
• Have received a tetanus vaccine within the previous month
• Refuses vaccination or does not consent
• Nomadic population travelling before the end of the study
• Pregnant women due to deliver within 2 weeks

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cold chain	Tetanus toxoid vaccine	Group vaccinated with tetanus toxoid vaccine kept in cold chain
CTC	Tetanus toxoid vaccine	Group vaccinated with tetanus toxoid vaccine kept in controlled temperature chain

Primary Outcome Measures

Name	Time	Method
Protective level of anti-tetanus antibodies	4 weeks after second dose of vaccine	The proportion of women who achieve a protective level of anti-tetanus antibodies after 2 doses of vaccine kept in CTC is not lower to the proportion of women who achieve a protective level of anti-tetanus antibodies after 2 doses of vaccine kept in cold chain.

Secondary Outcome Measures

Name	Time	Method
Vaccine stability	30 days after exposure to ambient temperatures	Verify the stability of the vaccine (potency, safety, pH and adsorption) after exposure to ambient temperatures
Antibody levels	4 weeks after second dose of vaccine	Evaluate the percentage increase in antibody levels in women who have received 2 doses of vaccine maintained in CTC and in women who have received 2 doses of vaccine maintained in cold chain
Adverse events	30 min and 7 days after vaccination	Compare the adverse events in the group vaccinated with the vaccine kept in CTC and the group vaccinated with the vaccine kept in cold chain.

Trial Locations

Locations (1)

Moïssala health district; 🇹🇩 Moïssala, Chad